Canada Markets closed
  • S&P/TSX

    19,620.13
    +43.13 (+0.22%)
     
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • DOW

    32,803.47
    +76.67 (+0.23%)
     
  • CAD/USD

    0.7734
    -0.0040 (-0.5166%)
     
  • CRUDE OIL

    88.53
    -0.01 (-0.01%)
     
  • BTC-CAD

    30,048.32
    -124.03 (-0.41%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • GOLD FUTURES

    1,792.40
    -14.50 (-0.80%)
     
  • RUSSELL 2000

    1,921.82
    +15.36 (+0.81%)
     
  • 10-Yr Bond

    2.8400
    +0.1640 (+6.13%)
     
  • NASDAQ

    12,657.55
    -63.04 (-0.50%)
     
  • VOLATILITY

    21.15
    -0.29 (-1.35%)
     
  • FTSE

    7,439.74
    -8.32 (-0.11%)
     
  • NIKKEI 225

    28,175.87
    +243.67 (+0.87%)
     
  • CAD/EUR

    0.7591
    +0.0009 (+0.12%)
     

Lonza's full-year core EBITDA up 20.7% on vaccine demand

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
FILE PHOTO: Logo of Swiss contract drug maker Lonza is seen in Basel
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Ludwig Burger

(Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines.

Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. That was broadly in line with an analyst consensus posted on its website.

The company, which is a key supplier of vaccine maker Moderna, is stepping up investments as it banks on long-term growth in the biopharmaceuticals sector well beyond the pandemic. [nL8N2R81GF]

For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.

(Reporting by Ludwig BurgerEditing by Riham Alkousaa, editing by Kirsti Knolle)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting